Comparative Pharmacology
Head-to-head clinical analysis: GRISACTIN ULTRA versus NILSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISACTIN ULTRA versus NILSTAT.
GRISACTIN ULTRA vs NILSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to tubulin and disrupts microtubule function, inhibiting fungal cell division and nucleic acid synthesis.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
500 mg orally once daily or 250 mg orally twice daily; for severe infections, 500 mg twice daily or 250 mg three times daily. Maximum daily dose: 1 g. Administer with or after meals.
Topical: Apply 100,000 units/g cream or ointment to affected area twice daily. Oral suspension: 100,000 units/mL; 4-6 mL swish and swallow four times daily for 14 days. Oral tablets: 500,000 units; 1-2 tablets three times daily.
None Documented
None Documented
Terminal elimination half-life ranges from 6.5 to 9 hours (mean ~7.5 hours) in patients with normal hepatic function; prolonged in hepatic impairment.
Not well-defined due to minimal systemic absorption following oral or topical administration; estimated to be <1 hour in systemic circulation if absorbed.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine; approximately 30-50% of a dose is eliminated in feces as metabolites, with minor biliary excretion.
Primarily via feces as unchanged drug; negligible urinary excretion (<1%).
Category C
Category C
Antifungal
Antifungal